Antibacterial activity of 3-methylbenzo[d]thiazol-methylquinolinium derivatives and study of their action mechanism

Abstract

The increasing incidence of multidrug resistant bacterial infection renders an urgent need for the development of new antibiotics. To develop small molecules disturbing FtsZ activity has been recognized as promising approach to search for antibacterial of high potency systematically. Herein, a series of novel quinolinium derivatives were synthesized and their antibacterial activities were investigated. The compounds show strong antibacterial activities against different bacteria strains including MRSA, VRE and NDM-1 Escherichia coli. Among these derivatives, a compound bearing a 4-fluorophenyl group (A2) exhibited a superior antibacterial activity and its MICs to the drug-resistant strains are found lower than those of methicillin and vancomycin. The biological results suggest that these quinolinium derivatives can disrupt the GTPase activity and dynamic assembly of FtsZ, and thus inhibit bacterial cell division and then cause bacterial cell death. These compounds deserve further evaluation for the development of new antibacterial agents targeting FtsZ.

Introduction

Antimicrobial resistance is one of the major actual health plague. Due to the overuse and abuse of antibacterial drugs, bacteria develop resistance to conventional antibiotics at an alarming speed, and the treatment of antibiotic-resistant bacterial infections becomes more and more difficult¹. Methicillin-resistant Staphylococcus auerus (MRSA) is a typical example of Gram-positive bacteria which have already shown resistance to the wildly prescribed antibiotics including methicillin as well as other β-lactam antibiotics, such as oxacillin and nafcillin. MRSA is responsible for many illnesses, ranging from skin infections to pneumonia. In 2011, the CDC estimated there were about 11,285 MRSA related deaths in United Stated². This situation is also critical in Gram-negative bacteria infections. The WHO has released a list of the drug-resistant bacteria which new antibiotics are desperately needed. In this list, carbapenem resistant Gram-negative organisms are in the critical priority³. For example, the recently emerging New Delhi metallo-β-lactamase 1 (NDM-1) superbugs has made almost of the first-line clinical antibiotics ineffective⁴. Infections by antibiotic-resistant bacteria lead to high morbidity and mortality rates, however, there are limited treatment options for these infections to-date. There is an urgent need for the development of new antibacterial agents with innovative mechanisms of action to against the multidrug-resistant bacteria⁵.

Bacterial cell division is an essential process that has not yet been targeted by clinically approved antibiotics and thus it is a very important research area for antibacterial discovery. Bacterial cell division is believed to be critical in new antibiotic development because it is an essential process for bacterial survival and the bacterial divisome possesses a complex set of biochemical machinery that contains many proteins. The most important division proteins are widely conserved among bacterial pathogens and they are almost absent in eukaryotic cells⁶. Among these proteins, filamentous temperature sensitive protein Z (FtsZ) plays a critical role in cell division process. To initiate cell division, FtsZ assembles into protofilaments in a GTP dependent manner and forms a ring-like structure (Z-ring) at the division site^7,8. Z-ring functions as a scaffold for the assembly of other cell division proteins to form bacterial divisome. Although the composition and the interdependency of divisome members may vary among different species, most bacteria depend on FtsZ as the central pacemaker protein⁹. Therefore, FtsZ is an attractive target for the development of novel antimicrobials.

Over the past decade, only few inhibitors of FtsZ have been reported showing the potency of disrupting FtsZ function and causing filamentation in bacteria^10–12. However, these examples reveal that FtsZ targeting compounds inhibit bacterial growth through disrupting the dynamic polymerization and/or GTP hydrolysis of FtsZ. Among the FtsZ inhibitors, zantrin Z3 (Figure 1(A)) and its analogs which contain a benzo[g]quinazoline core can effectively inhibit the GTPase activity of FtsZ and display a broad-spectrum and modest antibacterial activity against a panel of bacteria^13,14. Further SAR study revealed that replacing benzo[g]quinazoline by a smaller quinazoline, these molecules retain inhibitory activity on the FtsZ protein¹⁴. A quinoline derivative (Figure 1(B)) were reported to inhibited the growth of Mycobacterium tuberculosis through disrupting the polymerization of MtbFtsZ¹⁵. In addition, recent studies revealed that quinolinium derivatives (Figure 1(C)) have a potent antibacterial activity against drug resistant strains, including MRSA and Vancomycin-Resistant E. faecalis^16,17. Based on our previous findings and experience on searching for novel potent anti-FtsZ agents through molecular design and synthesis^18–24, we herein reported a new series of compounds (A1–A16) with a general molecular scaffold of 3-methylbenzo[d]thiazol-methylquinolinium (Figure 1(D)), in which we systemically varying the substituent groups linked at the ortho-position of 1-methylquinolinium core and investigated their antimicrobial activity with respect to different styryl substituents and mode of action targeting FtsZ.

Figure 1.

Structures of zantrin Z3, quinoline derivative, quinolinium derivative, and 3-methylbenzo[d]thiazol-methylquinolinium derivatives.

Materials and methods

Chemistry

General experimental

Melting points (m.p.) were determined using a SRS Opti Mel automated melting point instrument without correction. ¹H and 13C NMR spectra were recorded using TMS as the internal standard in DMSO-d₆ with a Bruker BioSpin GmbH spectrometer at 400 and 100 MHz, respectively. Mass spectra (MS) were recorded on Bruker amaZon SL mass spectrometer with an ESI or ACPI mass selective detector. Reactions progress and compounds were checked by TLC with Merck silica gel 60F-254 glass plates. All chemicals were purchased from commercial sources unless otherwise specified, and all the solvents were analytical grade. The purities of synthesized compounds were confirmed by HPLC with a dual pump Shimadzu LC-20A system equipped with a photo-diode array detector and a C18 column (250 × 4.6 mm, 5 μM YMC) and eluted with acetonitrile/water (47:53) containing 0.5% acetic acid at flow rate of 1.0 ml/min.

Synthesis of 4-chloro-1,2-dimethylquinolin-1-ium iodide (I1)

Iodomethane (0.42 ml, 6.74 mmol) was added into the solution of 4-Chloro-2-methylquinoline (0.2 g, 1.12 mmol) in sulfolane (10 ml) was added. The reaction mixture was stirred at 50 °C for 20 h, cooled and anhydrous ether is added after the shock, suction filtration, the solid was washed with anhydrous diethyl ether, dried in vacuum to give of I1 (0.343 g, 95%): mp: 245–247 °C. ¹H NMR (400 MHz, DMSO-d₆): δ 8.90 (s, 1H), 8.67 (d, J = 9.0 Hz, 1H), 8.26 (ddd, J = 8.7, 7.1, 1.4 Hz, 1H), 8.12 (t, J = 7.6 Hz, 1H), 8.05 (t, J = 7.5 Hz, 1H), 4.43 (s, 3H), 2.99 (d, J = 6.2 Hz, 3H). ESI-MS: m/z 192.1 [M − I]⁺.

Synthesis of 1, 2-dimethyl–benzo[d]thiazol-1-ium iodide (I2)

A mixture of 2-methylbenzo[d]thiazole (0.25 g, 1.68 mmol), iodomethane (0.63 ml, 10.08 mmol) and anhydrous ethanol (10 ml) was stirred at reflux temperature for 15 h. After cooling, the mixture was dried over anhydrous ethanol and chloroform oscillating suction filtered. The precipitate was washed with chloroform and a small amount of ethanol, then vacuum dried to give I2 (0.447 g, 91.7%): mp: 232–235 °C. ¹H NMR (400 MHz, DMSO-d₆): δ 8.44 (d, J = 8.1 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 7.90 (t, J = 7.8 Hz, 1H), 7.81 (t, J = 7.7 Hz, 1H), 4.20 (s, 3H), 3.17 (s, 3H). ESI-MS: m/z 164.4 [M − I]⁺.

Synthesis of (Z)-1,2-dimethyl-4-((3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl) quinolin-1-ium iodide (I3)

I1 (0.5 g, 1.60 mmol), I2 (0.5 g, 1.75 mmol) and aqueous sodium bicarbonate solution (0.5 mol/l, 2 ml) were mixed with 10 ml methanol, and stirred at room temperature. After 1 h, 4 ml saturated KI solution was added to the reaction solution. After stirred another 15 min, I3 was obtained by washing with water and acetone, and dried in vacuum (0.475 g, 92%): mp: 268–271 °C. ¹H NMR (400 MHz, DMSO-d₆): δ 8.77 (d, J = 8.3 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.02–7.96 (m, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.59 (t, J = 7.7 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.33 (s, 1H), 6.84 (s, 1H), 4.06 (s, 3H), 3.98 (s, 3H), 2.87 (s, 3H). ESI-MS: m/z 319.0 [M − I]⁺.

General procedure for the synthesis of 3-methylbenzo[d]thiazol-methylquinolinium derivatives (A1-A16)

A mixture of I3 (0.072 g, 0.16 mmol), 4-methylpiperidine (0.5 ml), n-butanol (10 ml) and selected aldehyde (0.32 mmol) were mixed and stirred at reflux temperature for 3 h. After the mixture was cooled down and filtered by suction, the solid was washed with n-butanol and purified by using column chromatography to obtain the pure target compounds A1–A16.

2-((E)-4-chlorostyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene) methyl)quinolin-1-ium iodide (A1). Purple solid, yield 85%; mp 297–301 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (d, J = 8.4 Hz, 1H), 8.24 (d, J = 8.68 Hz, 1H), 8.08 (d, 1H), 8.02 (d, J = 7.4 Hz,3H), 7.84 (d, J = 4.5 Hz, 1H), 7.75 (m, J = 9.5 Hz, 3H), 7.65 (s, 1H), 7.56 (s, 3H), 7.45 (t, J = 8.3 Hz, 1H), 6.95 (s, 1H), 4.27 (s, 3H), 4.02 (s, 3H). 13C NMR (100 MHz, DMSO-d₆): δ 159.31, 154.79, 148.40, 140.95, 139.64, 139.49, 133.58, 130.62, 129.43, 128.50, 126.83, 125.82, 124.67, 124.14, 123.91, 123.48, 123.17, 118.73, 113.10, 111.03, 87.33, 37.56, 34.09. ESI-MS: [M − I]⁺ (C₂₇H₂₂ClN₂S⁺): m/z 441.0; HPLC retention time was 1.94 min.

2-((E)-4-fluorostyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl) quinolin-1-ium iodide (A2). Rufous solid, yield 85%; mp 293–296 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.69 (d, J = 8.4 Hz, 1H), 8.01 (dd, J = 29.3, 10.1 Hz, 4H), 7.94–7.89 (m, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.63 (dd, J = 19.6, 11.2 Hz, 3H), 7.54 (d, J = 14.5 Hz, 1H), 7.44 (s, 1H), 7.34 (dd, J = 19.2, 8.3 Hz, 3H), 6.79 (s, 1H), 4.07 (s, 3H), 3.92 (s, 3H). 13C NMR (100 MHz, DMSO-d₆): δ 159.83, 152.07, 148.00, 140.82, 139.79, 139.32, 133.66, 132.22, 131.24, 131.16, 128.49, 126.90, 125.61, 124.66, 124.27, 123.85, 123.42, 121.96, 118.89, 116.47, 116.25, 113.09, 108.23, 88.29, 38.53, 34.13. ESI-MS: [M − I]⁺ (C₂₇H₂₂FN₂S⁺): m/z 425.0; HPLC retention time was 3.63 min.

2-((E)-4-bromostyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene) methyl)quinolin-1-ium iodide (A3). Rufous solid, yield 87%; Mp 307–309 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 8.76 (d, J = 8.2 Hz, 1H), 8.18 (d, J = 8.2 Hz, 1H), 8.05 (d, J = 7.6 Hz, 1H), 8.00 (d, J = 7.3 Hz, 1H), 7.90 (d, J = 7.8 Hz, 2H), 7.86 – 7.70 (m, 5H), 7.63 (d, J = 19.0 Hz, 3H), 7.44–7.37 (m, 1H), 6.92 (s, 1H), 4.12 (d, J = 30.4 Hz, 3H), 4.01 (s, 3H). 13C NMR (100 MHz, DMSO-d₆): δ 159.57, 154.63, 148.40, 140.95, 139.64, 139.49, 133.58, 130.62, 129.43, 128.50, 126.83, 125.82, 124.67, 124.14, 123.91, 123.48, 123.17, 118.73, 113.10, 111.03, 87.33, 37.56, 34.09. ESI-MS: [M − I]⁺ (C₂₇H₂₂BrN₂S⁺): m/z 486.9; HPLC retention time was 3.52 min.

2-((E)-2,4-dichlorostyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)quinolin-1-ium iodide (A4). Purple solid, yield 87%; Mp 271–275 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.74 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 7.0 Hz, 2H), 7.85 (d, J = 15.8 Hz, 1H), 7.73 (t, J = 17.6 Hz, 4H), 7.59 (t, J = 10.7 Hz, 2H), 7.52 (s, 1H), 7.39 (d, J = 7.2 Hz, 1H), 6.91 (s, 1H), 4.11 (s, 3H), 3.98 (s, 3H). 13C NMR (100 MHz, DMSO-d₆): δ 159.90, 151.68, 148.25, 140.85, 139.37, 135.67, 134.83, 134.75, 133.87, 132.23, 130.11, 129.89, 128.67, 128.48, 127.11, 125.98, 125.67, 124.94, 123.97, 123.19, 118.98, 113.33, 108.68, 88.78, 38.68, 34.31. ESI-MS: [M − I]⁺ (C₂₇H₂₁Cl₂N₂S⁺): m/z 475.0; HPLC retention time was 4.29 min.

1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-2-((E)-4-methyl styryl)quinolin-1-ium iodide (A5). Red solid, yield 85%; mp 275–278 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.77 (d, J = 8.3 Hz, 1H), 8.19 (d, J= 8.8 Hz, 1H), 8.07 (d, J= 7.8 Hz, 1H), 8.00 (t, J= 7.9 Hz, 1H), 7.85 (d, J = 7.9 Hz, 2H), 7.75 (dd, J = 9.7, 5.6 Hz, 3H), 7.63 (dt, J = 15.6, 9.9 Hz, 3H), 7.43–7.34 (m, 3H), 6.92 (s, 1H), 4.17 (s, 3H), 4.00 (d, J = 8.1 Hz, 3H), 2.41 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 159.92, 152.60, 148.26, 141.32, 141.05, 140.79, 139.52, 133.74, 132.99, 130.03, 128.95, 128.55, 126.97, 125.69, 124.69, 124.27, 124.01, 123.48, 121.10, 119.03, 113.14, 108.44, 88.27, 38.53, 34.12, 21.57. ESI-MS: [M − I]⁺ (C₂₈H₂₅N₂S⁺): m/z 421.2; HPLC retention time was 3.38 min.

2-((E)-4-(dimethylamino)styryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-y lidene)methyl)quinolin-1-ium iodide (A6). Purple solid, yield 89%; mp 301–304 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (d, J = 8.3 Hz, 1H), 8.13 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.97–7.92 (m, 1H), 7.79 (d, J = 8.9 Hz, 2H), 7.71 (d, J = 7.8 Hz, 1H), 7.69–7.64 (m, 2H), 7.63 (s, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.43 (d, J = 15.7 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 6.79 (d, J = 9.1 Hz, 3H), 4.13 (s, 3H), 3.94 (s, 3H), 3.05 (s, 6H). 13C NMR (100 MHz, DMSO-d₆): δ 158.77, 153.24, 152.30, 147.53, 142.83, 141.10, 139.57, 133.43, 130.97, 128.40, 126.63, 125.57, 124.30, 124.05, 123.92, 123.38, 123.11, 118.93, 115.10, 112.74, 112.16, 108.03, 87.58, 38.28, 33.91. ESI-MS: [M − I]⁺ (C₂₉H₂₈N₃S⁺): m/z 450.1; HPLC retention time was 5.44 min.

1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-2-((E)-4-(methyl thio)styryl)quinolin-1-ium iodide (A7). Rufous solid, yield 90%; mp 293–295 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (d, J = 7.8 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.06–8.02 (m, 1H), 8.00–7.95 (m, 1H), 7.87 (d, J = 8.5 Hz, 2H), 7.76–7.68 (m, 3H), 7.64 (s, 1H), 7.61–7.55 (m, 2H), 7.42–7.35 (m, 3H), 6.87(s, 1H), 4.13(s, 3H), 3.97 (d, J = 3.7 Hz, 3H), 2.56 (s, 3H). 13C NMR (100 MHz, DMSO-d₆): δ 159.81, 152.50, 148.16, 142.08, 141.04, 140.86, 139.51, 133.71, 132.08, 129.41, 128.54, 126.94, 126.07, 125.67, 124.68, 124.26, 123.98, 123.44, 120.95, 119.01, 113.11, 108.42, 38.53, 34.11, 14.77. ESI-MS: [M − I]⁺ (C₂₈H₂₅N₂S₂⁺): m/z 453.0; HPLC retention time was 3.45 min.

2-((E)-4-methoxystyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene) methyl)quinolin-1-ium iodide (A8). Brown solid, yield 86%; mp 263–267 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (d, J = 8.4 Hz, 1H), 8.08 (dd, J = 14.8, 8.3 Hz, 2H), 7.99–7.89 (m, 3H), 7.73 (t, J = 7.6 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.63–7.56 (m, 3H), 7.51 (s, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.82 (s, 1H), 4.11 (s, 3H), 3.96 (s, 3H), 3.91 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 160.41, 158.29, 151.39, 146.68, 140.01, 139.75, 138.21, 132.41, 129.64, 127.29, 127.12, 125.65, 124.43, 123.36, 123.04, 122.70, 122.25, 118.06, 117.75, 113.67, 111.81, 106.95, 86.87, 54.80, 37.30, 32.91. ESI-MS: [M − I]⁺ (C₂₈H₂₅N₂OS⁺): m/z 437.0; HPLC retention time was 2.95 min.

2-((E)-3-methoxystyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene) methyl)quinolin-1-ium iodide (A9). Rufous solid, yield 87%; mp 252–256 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.50 (d, J = 8.5 Hz, 1H), 7.83–7.73 (m, 3H), 7.70 (d, J = 7.7 Hz, 1H), 7.56 (dd, J = 15.5, 11.8 Hz, 2H), 7.39 (dd, J = 16.2, 9.3 Hz, 3H), 7.31 (d, J = 8.2 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.09 (s, 1H), 6.99 (t, J = 7.4 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 6.52 (s, 1H), 3.81 (d, J = 12.7 Hz, 3H), 3.74 (s, 3H), 3.65 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 158.57, 157.74, 152.11, 147.18, 140.32, 138.85, 135.87, 133.43, 132.33, 128.64, 128.40, 126.69, 125.29, 124.49, 123.62, 123.54, 123.47, 122.65, 121.28, 121.09, 118.61, 112.79, 111.99, 107.86, 87.84, 56.28, 38.22, 34.02. ESI-MS: [M − I]⁺ (C₂₈H₂₅N₂OS⁺): m/z 437.0; HPLC retention time was 3.14 min.

2-((E)-3,4-dimethoxystyryl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)quinolin-1-ium iodide (A10). Brown solid, yield 89%; mp 266–270 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (d, J = 8.2 Hz, 1H), 8.14 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.99–7.95 (m, 1H), 7.91 (d, J = 7.3 Hz, 1H), 7.69 (s, 1H), 7.62 (d, J = 6.7 Hz, 2H), 7.58 (s, 3H), 7.47 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 7.6 Hz, 2H), 7.07 (d, J = 8.2 Hz, 1H), 6.85 (s, 1H), 6.65 (s, 1H), 4.16 (s, 3H), 3.97 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 158.57, 157.74, 152.11, 147.13, 140.32, 138.85, 135.87, 133.43, 132.33, 128.64, 128.40, 126.69, 125.29, 124.49, 123.62, 123.54, 123.47, 122.65, 122.41, 87.70, 56.28, 37.96, 33.94. ESI-MS: [M − I]⁺ (C₂₉H₂₇N₂O₂S⁺): m/z 467.0; HPLC retention time was 5.72 min.

1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-2-((E)-2-(pyridine-3-yl)vinyl)quinolin-1-ium iodide (A11). Rufous solid, yield 88%; mp 288–291 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 9.10 (s, 1H), 8.77 (s, 1H), 8.66 (d, J = 3.7 Hz, 1H), 8.39 (d, J = 7.3 Hz, 1H), 8.17 (s, 1H), 8.06 (d, J = 7.5 Hz, 1H), 7.99 (s, 1H), 7.91 (d, J = 15.9 Hz, 1H), 7.74 (s, 2H), 7.67 (d, J = 18.3 Hz, 1H), 7.65–7.52 (m, 3H), 7.41 (s, 1H), 6.91 (s, 1H), 4.16 (s, 3H), 4.00 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 160.23, 151.88, 151.12, 150.40, 148.29, 140.98, 139.45, 137.63, 135.15, 133.81, 131.47, 128.59, 127.05, 125.70, 124.83, 124.41, 124.37, 124.29, 123.98, 123.45, 119.01, 113.27, 108.47, 88.58, 38.62, 34.22. ESI-MS: [M − I]⁺ (C₂₆H₂₂N₃S⁺): m/z 408.0; HPLC retention time was 1.97 min.

2-((E)-2–(1H-indol-3-yl)vinyl)-1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)quinolin-1-ium iodide (A12). Rufous solid, yield 85%; mp 298–303 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (s, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.20 (s, 1H), 8.09 (d, J = 7.3 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.88 (dd, J = 15.5, 5.5 Hz, 2H), 7.63 (t, J = 7.6 Hz, 1H), 7.51 (q, J = 8.4 Hz, 4H), 7.33–7.23 (m, 4H), 6.70 (d, J = 8.5 Hz, 1H), 4.07 (s, 3H), 3.83 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 158.34, 153.65, 147.23, 140.96, 139.40, 136.84, 133.30, 128.29, 126.47, 125.49, 125.13, 124.14, 123.92, 123.80, 123.38, 123.26, 121.71, 120.70, 118.78, 114.21, 113.98, 113.05, 112.54, 107.63, 87.39, 38.20, 33.84. ESI-MS: [M − I]⁺ (C₂₉H₂₄N₃S⁺): m/z 446.1; HPLC retention time was 2.81 min.

1-methyl-4-((E)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-2-((E)-2-(naphth alen-2-yl)vinyl)quinolin-1-ium iodide (A13). Black solid, yield 85%; mp 299–304 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.78 (d, J = 8.3 Hz, 1H), 8.41 (s, 1H), 8.18 (t, J = 8.1 Hz, 2H), 8.11–8.04 (m, 2H), 8.01 (d, J = 4.9 Hz, 3H), 7.91 (s, 1H), 7.85 (s, 1H), 7.75 (t, J = 8.6 Hz, 2H), 7.67 (s, 1H), 7.65–7.56 (m, 3H), 7.40 (t, J = 7.4 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 4.20 (s, 3H), 3.99 (s, 3H). 13C NMR (100 MHz, DMSO-d₆): δ 159.99, 152.42, 148.28, 141.24, 141.06, 139.55, 134.15, 133.77, 133.39, 133.34, 130.41, 129.05, 128.89, 128.56, 128.30, 127.90, 127.44, 126.99, 125.73, 124.72, 124.58, 124.32, 124.05, 123.52, 122.55, 119.06, 113.19, 108.54, 88.44, 38.63, 34.18. ESI-MS: [M − I]⁺ (C₃₁H₂₅N₂S⁺): m/z 457.0; HPLC retention time was 6.90 min.

1-methyl-4-((Z)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-2-((1E,3E)-4-phenylbuta-1,3-dien-1-yl)quinolin-1-ium iodide (A14). Brown solid, yield 80%; mp 254–257 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (t, J = 10.7 Hz, 1H), 8.10 (dd, J = 18.2, 9.6 Hz, 2H), 7.97–7.92 (m, 1H), 7.74–7.68 (m, 2H), 7.67–7.61 (m, 2H), 7.60–7.51 (m, 3H), 7.45 (dd, J = 13.6, 5.9 Hz, 2H), 7.42–7.35 (m, 3H), 7.31 (d, J = 15.2 Hz, 2H), 6.83 (d, J = 9.2 Hz, 1H), 4.06 (d, J = 14.2 Hz, 3H), 3.97 (d, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 159.64, 151.84, 147.88, 141.95, 141.06, 140.24, 139.50, 136.52, 133.65, 129.66, 129.53, 128.60, 128.54, 127.64, 126.90, 125.64, 125.09, 124.64, 124.24, 123.96, 123.48, 118.98, 113.11, 108.00, 88.23, 38.24, 34.12. ESI-MS: [M − I]⁺ (C₂₉H₂₅N₂S⁺): m/z 433.2; HPLC retention time was 1.70 min.

2-((1E,3E)-4–(4-fluorophenyl)buta-1,3-dien-1-yl)-1-methyl-4-((Z)-(3-methylbenzo [d]thiazol-2(3H)-ylidene)methyl)quinolin-1-ium iodide (A15). Trovirens solid, yield 87%; mp 281–284 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (d, J = 8.3 Hz, 1H), 8.09 (t, J = 9.5 Hz, 2H), 7.98–7.93 (m, 1H), 7.70 (dd, J = 15.8, 7.2 Hz, 4H), 7.61–7.56 (m, 1H), 7.55–7.49 (m, 2H), 7.42–7.37 (m, 1H), 7.31 (t, J = 8.8 Hz, 4H), 7.27 (s, 1H), 6.85 (s, 1H), 4.08 (s, 3H), 3.97 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆): δ 164.19, 161.73, 159.63, 151.82, 147.89, 141.86, 141.05, 139.49, 138.96, 133.64, 133.20, 133.17, 129.74, 129.66, 128.53, 128.44, 126.89, 125.63, 124.99, 124.62, 124.23, 123.96, 123.47, 118.93, 116.60, 116.38, 113.09, 108.01, 88.24, 38.23, 34.14. ESI-MS: [M − I]⁺ (C₂₉H₂₄FN₂S⁺): m/z 451.0; HPLC retention time was 1.71 min.

2-((1E,3E)-4–(4-(dimethylamino)phenyl)buta-1,3-dien-1-yl)-1-methyl-4-((Z)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)quinolin-1-ium iodide (A16). Atrovirens solid, yield 85%; mp: 289–294 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 8.9 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.95 (t, J = 7.8 Hz, 1H), 7.73–7.68 (m, 2H), 7.59 (dd, J = 13.5, 7.0 Hz, 3H), 7.49 (d, J = 8.7 Hz, 2H), 7.39 (t, J = 7.6 Hz, 1H), 7.17 (dd, J = 24.7, 13.8 Hz, 3H), 6.83–6.76 (m, 3H), 4.09 (d, J = 8.5 Hz, 3H), 3.96 (s, 3H), 3.00 (d, J = 11.7 Hz, 6H). ¹³C NMR (100 MHz, DMSO-d₆): δ 158.75, 152.13, 151.49, 147.13, 143.68, 142.22, 140.98, 139.42, 133.35, 129.38, 128.39, 126.59, 125.49, 124.30, 124.08, 124.00, 123.81, 123.62, 123.41, 120.93, 118.77, 112.78, 112.53, 107.66, 87.68, 37.99, 33.94. ESI-MS: [M − I]⁺ (C₃₁H₃₀N₂S⁺): m/z 476.1. HPLC retention time was 4.89 min.

Antimicrobial susceptibility assays

Antimicrobial susceptibility tests were conducted in 96-well microplates using the broth microdilution procedure in accordance to the Clinical and Laboratory Standards Institute (CLSI) guidelines²⁵. Cation-adjusted Mueller Hinton broth for all the S. aureus strains, including MRSA, or brain heart infusion broth for antibiotic-susceptible E. faecium ATCC 49624 and E. faecalis ATCC 29212, vancomycin-resistant E. faecium ATCC 700221 and E. faecalis ATCC 51575, or Mueller Hinton broth for the other strains were used in the assays. After incubation for 18 h at 37 °C, the absorbance at 600 nm (A₆₀₀) was recorded using a microplate reader (Bio-Rad laboratory Ltd., UK) and the percentage of bacterial cell inhibition with respect to vehicles (1% DMSO) was calculated. The MIC was defined as the lowest compound concentration at which the growth of bacteria was inhibited by ≥90%. Three independent assays were performed for each test.

Time-killing curve determination

A growing culture of S. aureus ATCC 29213 or E. coli ATCC25922 were diluted to approximately 10⁵ CFU mL⁻¹ in volumes of Cation-adjusted Mueller Hinton broth or Mueller Hinton broth, respectively, containing various concentrations of tested compound. Cultures were incubated with shaking at 37 °C. At the appropriate time intervals, 100 μL samples were removed for serial dilution in 900 μL volumes of corresponding medium, and 100 μL volumes from three dilutions were spread on to MH agar. Cell counts (CFU ml⁻¹) were enumerated after incubating the plates at 37 °C for 24 h.

GTPase activity test

FtsZ protein in the biological tests was prepared as our previous report²¹. The GTPase activity of SaFtsZ was measured in 96-well microplates using a phosphate assay Kit according to previous description²⁰. FtsZ (3.5 μM) was preincubated with different concentrations of tested compounds in 20 mM Tris buffer (pH 7.4, 0.01%Triton X-100 to avoid compound aggregation) at room temperature. 5 mM of MgCl₂ and 200 mM of KCl were added after 10 min incubation. Reactions were started with the addition of 500 mM GTP and incubated in a water bath at 37 °C. After 30 min, the reactions were quenched by adding 100 μL of Cytophos reagent for 10 min. Inorganic phosphate was quantified by measuring the absorbance at 650 nm with a microplate reader.

Light scattering assay

The FtsZ polymerization was measured using 90° light scattering in a fluorescence spectrometer at 37 °C. Excitation and emission wavelengths were set at 600 nm with a slit width of 2.5 nm. FtsZ (5 μM) in 20 mM of Tris buffer (pH 7.4, containing 0.01%Triton X-100 to avoid compound aggregation) was placed in a fluorometer cuvette, and the polymerization reaction was started by consecutive additions of 20 mM KCl, 5 mM MgCl₂, 1 mM GTP, and different concentrations of tested compound.

Transmission electron microscopy (TEM)

FtsZ (13.5 μM) was incubated with different concentrations of tested compounds in 20 mM Tris buffer (pH 7.4) at room temperature. After 10 min incubation, 5 mM MgCl₂, 50 mM KCl, and 1 mM GTP were added to the reaction mixtures and incubated at 37 °C for another 10 min. Then, 10 μL of the sample mixtures were dropped on a glow-discharged Formvar carbon-coated copper grid. The grids were subsequently subjected to negative staining using 10 μL of 0.5% phosphotungstic acid for 1 min, air-dried and digital images of the specimen were obtained from a transmission electron microscope (JEOL model JEM 2010).

Bacterial morphology study

The B. subtilis 168 was grown in LB medium. The cultures at an A₆₀₀ of 0.01 from an overnight culture were inoculated in the same medium containing different concentrations of the tested compound and grown at 37 °C for 4 h. The cells for morphology studies were harvested and resuspended in 100 μL of PBS buffer containing 0.25% agarose. 10 μL of the suspension mixture were then placed on a microscopic slide and the morphology of the bacterial cells was observed under a light phase-contrast microscope.

Molecular modeling

The molecular modeling were performed using Discovery Studio 2016. The X-ray crystal structure of FtsZ was downloaded from the PDB database (PDB entry: 4DXD; resolution: 2.0 Å)²⁶. Co-crystal ligands and water molecules were removed from the structure and the protein was prepared for docking using automated procedure of Discovery Studio. The structures of A2 was sketched and minimized using the Discovery Studio molecule preparation tools. The automated docking study was carried out using DS-CDocker protocol in the Discovery Studio. The highest scoring poses were visually inspected.

Cytotoxicity test of quinolinium derivatives

Selected quinolinium derivatives (A2 and A5) were tested with renal epithelial cells (HK-2) and Mouse fibroblasts cells (L929) to determine the cytotoxicity of eukaryotic mammalian cells. Cells were re-suspended in complete cell culture medium and the concentration was adjusted at approximately 1 × 10⁵ cells mL⁻¹. Cells seeded in the 96 wells microtitre plates for 24 h were used for the evaluation of the tested compounds. For the MTS assay, cells (5,000 per well) were seeded into 96-well plates. After treatment with compounds of different concentrations for 24h, cells were added with MTS at a final concentration of 0.3 mg/mL, followed by incubation for another 2h. The optical density (OD) of each well was determined at 490 nm (background subtraction at 690 nm) by a SpectraMax 340 microplate reader. The growth inhibitory ratio was calculated as follows: Growth inhibitory ratio = (A_control − A_sample)/A_control (where A is the OD value per well).

Results and discussions

Synthesis of target compounds

In the present study, compounds A1–A16 listed in Table 1 were synthesized from 4-chloro-2-methylquinoline as outlined in Scheme 1. Intermediate I1 (4-chloro-1,2-dimethylquinolin-1-ium iodide) and Intermediate I2 (2,3-dimethylbenzo[d]thiazol-3-ium iodide) was obtained by the reaction of 4-chloro-2-methylquinoline and 2-methylbenzo[d]thiazole with iodomethane. Then the key intermediate (Z)-1,2-dimethyl-4-((3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl) quinolin-1-ium iodide (I3) was prepared by the reaction of I1 and I2 by following the reported procedures²⁷. The target compounds with different styryl substituents introduced at ortho-position of I3 were then achieved by the reaction of I3 with a variety of aromatic aldehydes. The target compounds were obtained with high isolated yields (80–90%) and were characterized by MS and NMR. All the spectral data were in agreement with the proposed structures. The purities of these compounds were confirmed to be above 95% using HPLC analysis.

Table 1.

List of 3-methylbenzo[d]thiazol-methylquinolinium derivatives (A1–A16).

Scheme 1.

Synthesis route of 3-methylbenzo[d]thiazol-methylquinolinium derivatives. Reagents and conditions: (a) iodomethane, tetramethylene sulfone, 50 °C, reflux; (b) iodomethane, absolute ethanol, 80 °C, reflux; (c) NaHCO₃, methanol, room temperature; (d) aromatic aldehydes, 4-methylpiperidine, n-butanol, 135 °C, reflux.

In vitro antibacterial activity

The antibacterial activities of the compounds were first evaluated by using a standard two-fold micro-dilution assay in Mueller–Hinton broth against a panel of drug-sensitive bacterial strains, including B. subtilis 168, S. aureus (ATCC 29213), E. coli (ATCC 25922), E. faecium (ATCC 49624), E. faecalis (ATCC 29212) and S. epidermidis (ATCC 12228). Methicillin, vancomycin, and berberine were tested under the same assay conditions as reference compounds. The minimum inhibition concentration (MIC) results were summarized in Table 2. By comparing the results with berberine, all compounds tested exhibit a much superior antibacterial activity against the six selected drug-sensitive strains. It is noteworthy that compounds A2, A3, and A5 have the MIC values lower than 6 μg/mL, showing their efficacy is comparable to clinical antibiotics such as methicillin and vancomycin. From Table 2, the structural effects arising from different styryl substituents show strong influence on the antibacterial activity as indicated by their MIC values. It seems that the antibacterial activity of these new compounds is correlated with the size and the styryl substituents (R group). Compound A2 (para-fluorostyryl) and A5 (para-methylstyryl) were showing very similar MIC value in the experiment, while other substituents with increase molecular size, particularly A13–A16, the antibacterial activity were decreased. This is most probably due to the steric influence of the substituent in the binding domain of FtsZ protein.

Table 2.

Minimum inhibitory concentrations of compounds A1–A16 against a panel of drug-sensitive bacterial strains (μg/mL).

Cpd.	B. subtilis 168	S. aureus ATCC 29213	E. faecium ATCC 49624	E. faecalis ATCC 29212	S. epidermidis ATCC 12228	E. coli ATCC 25922
A1	4	4	8	8	4	12
A2	1.5	1.5	2	2	1	3
A3	2	2	4	4	2	6
A4	12	12	16	16	12	32
A5	2	2	2	2	2	3
A6	2	4	6	6	4	12
A7	4	4	8	8	4	12
A8	4	4	8	8	4	24
A9	8	8	16	16	8	48
A10	8	8	12	12	8	16
A11	6	6	8	8	6	16
A12	8	8	8	8	8	24
A13	12	16	16	16	12	32
A14	32	32	64	64	32	>64
A15	16	16	24	24	16	32
A16	24	24	32	32	24	64
Berberine	128	128	>192	>192	96	>192
Methicillin	0.5	1	4	6	0.5	4
Vancomycin	1	1	2	>64	0.5	2

Based on the antibacterial results of the drug-sensitive strains, six compounds with the best MIC values (A1–A3 and A5–A7) were selected for further evaluation against an extended panel of clinically relevant drug-resistant bacterial strains including MRSA (ATCC BAA41, ATCC 43300), Vancomycin-Resistant E. faecalis (ATCC 51575) and E. faecium (ATCC 700221), NDM-1 E. coli (ATCC BAA2469), P. aeruginosa (ATCC BAA2108). As shown in Table 3, the selected compounds exhibited potent activity against three MRSA strains with MIC values of 1.5–4 μg/mL. The MIC values are comparable to that of vancomycin. Among these compounds, A2 was the most effective with a MIC value of 1.5 μg/mL against MRSA, and showed more than 100-fold better antibacterial activity than that of berberine and methicillin. The growth of vancomycin-resistant E. Faecalis and E. faecium (VREs) were inhibited with MIC values of 2–8 μg/mL. The antibacterial effects of these quinolinium derivatives on the VREs were much better that of vancomycin and berberine (MICs >64 μg/mL) and were comparable to that of methicillin. When tested on the Gram-negative strains NDM-1 E. coli and P. aeruginosa, methicillin shows little effect on the gowth of thesesuperbugs even at a high concentration (192 μg/mL). It is noteworthy that A2 and A5 can effectively inhibit the growth of NDM-1 E. coli with a much lower MIC value of 3 μg/mL. Moreover, P. aeruginosa which is resistant to most of the clinical antibiotics can be effectively inhibited by our quinolinium derivatives A2 and A5 with the MIC values of 6–8 μg/mL.

Table 3.

The antibacterial activity of selected compounds against drug-resistant bacterial strains (μg/mL).

Cpd.	S. aureus ATCC BAA41a	S. aureus ATCC 33591a	S. aureus ATCC 43300a	E. faecalis ATCC 51575b	E. faecium ATCC 700221b	E. coli ATCC BAA2469c	P. aeruginosa ATCC BAA2108d
A1	4	4	4	8	8	12	32
A2	1.5	1.5	1.5	2	2	3	6
A3	2	2	2	4	4	6	24
A5	2	2	2	2	2	3	8
A6	4	4	4	6	6	12	24
A7	4	4	4	8	8	12	32
Berberine	192	192	192	>192	>192	>192	>192
Methicillin	>192	>192	>192	6	6	>192	>192
Vancomycin	2	2	2	>64	>64	6	>64

^aMethicillin-resistant S. aureus.

^bVancomycin-resistant strains.

^cE. coli expressing NDM-1 beta-lactamase.

^dA multidrug-resistant strain.

Time-killing curve determinations

To further investigate whether the antibacterial activities of 3-methylbenzo[d]thiazol-methylquinolinium derivatives are bactericidal or not, the viable counts for the determination of killing curves were performed as previous report²⁵. Time killing curves resulting from A2 against S. aureus ATCC 29213 and E. coli ATCC 25922 are presented in Figure 2. A significant reduction about 10³ CFU mL⁻¹ (99.9% of bacterial growth inhibited) was observed in 2 h at 2 × and 4 × MIC against S. aureus. These phenomena indicate that A2 can inhibit the growth of S. aureus quickly. Figure 2(A) showed that A2 at 1 × MIC concentration caused a reduction of 1 × 10² CFU mL⁻¹ for S. aureus in 4 h and is below the lowest detectable limit (10³ CFU mL⁻¹) in 24 h. In the E. coli bacterial survival assay, 4 × MIC of A2 can rapidly reduce the viable counts below the lowest detectable limit after 2 h incubation, and the counts at MIC concentration were maintained under the lowest detectable limit for over 24 h (Figure 2(B)). These results indicate that quinolinium derivatives can inhibit the bacteria growth quickly through the bactericidal mode.

Figure 2.

Time-killing curve of A2. (A) At time zero, samples of a growing culture of S. aureus ATCC 29213 were incubated with concentrations of A2 equivalent to 1 × (red), 2 × (green), or 4 × (blue) the MIC. (B) Samples of a growing culture of E. coli ATCC 25922 were incubated with concentrations of A2 equivalent to 1 × (red), 2 × (green), or 4 × (blue) the MIC. Vehicle (1% DMSO; black) was included. Samples were removed at the time intervals indicated for the determination of viable cell counts.

Effects of quinolinium derivatives on the GTPase activity of FtsZ

After examining the antibacterial activity of quinolinium derivatives, we further investigated their mode of action. Recent study reported that the antibacterial activity of zantrin Z3 and quinoline derivative (Figure 1) may due to their interferential effect on the GTPase activity of FtsZ^13–15. To confirm whether the antibacterial activity of our quinolinium derivatives also follows this mechanism, we studied the effects with three selected compounds (A2, A5, and A15) which possess different antibacterial activities, on the GTPase activity of purified S. aureus FtsZ (SaFtsZ). The results shown that the quinolinium derivatives inhibit GTP hydrolysis of FtsZ in a concentration-dependent manner. For example, A2 at the concentration of 4 μg/mL showed an inhibition of 45% and achieved to 70% inhibitory effect when using 16 μg/mL (Figure 3). Athough A5 and A15 being less effective on the inhibition experiments, the results demonstrated that the compounds are able to inhibit the proliferation of bacteria via influencing the GTPase activity of FtsZ.

Figure 3.

Inhibition of GTPase activity of SaFtsZ by quinolinium derivatives A2, A5 and A15.

Effects of quinolinium derivatives on the FtsZ polymerization

Recent studies revealed that the dynamic polymerization of FtsZ was determined by its guanosine triphosphatase activity^7,8. In order to understand the mechanism of antibacterial activities of these quinolinium derivatives, we used a light scattering assay to assess the impact of selected compounds on the polymerization dynamic of FtsZ. It was found that the selected compounds (A2, A5, and A15) at 4 μg/mL exhibited an obvious enhancement effect on FtsZ polymerization. Vancomycin (10 μg/mL) is also tested as a non-FtsZ-targeting control antibiotic. As expected, it dose not disrupt the FtsZ polymerization. As shown in Figure 4(A), A2 possesses a stronger impact than that of A5 and A15 on the FtsZ polymerization and this result is correlated with their effects on GTPase activity of FtsZ and the antibacterial activity. Figure 4(B) shows the time-dependent polymerization profiles of SaFtsZ in the absence and presence of A2 at a concentration range from 2 to 8 μg/mL. The results confirmed that A2 stimulates FtsZ polymerization in a concentration-dependent manner. The effect of A2 on FtsZ polymerization was also observed via transmission electron microscopy (TEM). It was found that the size of FtsZ polymers were sharply increased after the treatment with A2 at 4 μg/mL (Figure 5). These phenomena suggested that the inhibition of GTPase activity of FtsZ is attributed to the disruption of FtsZ polymerization dynamic.

Figure 4.

Effect of quinolinium derivatives on the polymerization of FtsZ. (A) Effect on the polymerization of FtsZ in the absence or in the presence of 4 μg/mL of compound A2, A5, and A15, or 10 μg/mL of vancomycin. (B) The polymerizations of FtsZ in the presence of compound A2 at the concentrations of 2, 4, and 8 μg/mL.

Figure 5.

Electron micrographs of FtsZ polymers in the absence (A) and in the presence (B) of 4 μg/mL of A2.

Effects of quinolinium derivatives on the morphology of B. subtilis

To further investigate the mechanism of the antibacterial activity of the quinolinium derivatives, we observed the bacterial morphology of B. subtilis incubated with/without A2 through an optical microscopy. In this assay, cetyltrimethylammonium bromide (CTAB, MIC is 1 μg/mL against B. subtilis), a membrane-targeting antiseptic agent and methicillin, a cell wall synthesis inhibitor were used as negative controls. Figure 6(A) shows that untreated B. subtilis cells have typical short rod morphology with cell lengths from 2 to 10 μm. After treatment with 1.5 μg/mL of A2, the cell morphology of B. subtilis was found to become long filament. Most of the cell lengths are longer than 20 μm (Figure 6(B)). On the other hand, cells treated with CTAB or methicillin at MIC concentration did not show any filamentation (Figures 6(C,D)), suggesting the antibacterial mechanism of these quinoliniium derivatives is different to that of CTAB and methicillin. It is noteworthy that similar cell elongation phenomena can also be found in other FtsZ inhibitors such as berberine and benzamide derivatives^19,28–30. These results strongly indicated that our quinolinium derivatives inhibit cell division through disrupting GTPase activity and dynamic polymerization of FtsZ, then leading to cell death.

Figure 6.

Inhibition of cell division by A2. Cells of B. subtilis 168 were grown in the absence (A), and presence of A2 (B), CTAB (C) and methicillin (D) at the MIC concentration. Scale Bar =10 μm.

Predicted binding mode of quinolinium derivative (A2) in FtsZ

To study the binding mode of our quinolinium derivatives in the FtsZ protein, molecular modeling was used to identify a potential binding site for these small molecules in the FtsZ. A 2.01 Å crystal structure of S. aureus FtsZ apo-form²⁶ and A2 were used as models for this purpose. The highest docking score suggested that the ligand bind near the T7-loop and H7-helix of FtsZ (Figure 7(A)). Since the binding site is a relatively narrow cleft composed by T7-loop, H7-helix and a four-stranded β-sheet, the substrate requires some degree of planarity in its structure to fit in. The docking results suggested that a large number of favorable hydrophobic interactions occur between the molecule and the side chains of Asp199, Leu200, Met226, Ile228, Val297, Thr309 and Ile311. Moreover, the cationic pyridinium of A2 is predicted to participate in the charge interaction with the negative charged side chain of Asp199 (Figure 7(B)).

Figure 7.

(A) Quinolinium derivative (A2) was predited to bind into the C-terminal interdomain cleft of FtsZ; (B) predicted interactions between A2 and the amino acids of FtsZ.

Cytotoxicity of quinolinium derivatives

To probe for any potential mammalian cytotoxicity, the MTS tetrazolium assay was used to assess the cytotoxicity of selected quinolinium derivatives, which possess better antibacterial activity than other derivatives (A2 and A5), against two mammalian cell lines (HK-2, L929). Both tested compounds were found to be minimally toxic to these cell types, with 50% inhibitory concentrations (IC50s) higher than 40 μg/mL (Table 4), which are much higher than their MIC values (1.5 to 3.0 μg/mL) against MRSA and VRE bacterial strains (Table 3), indicating no significant toxicity towards normal mammalian cells.

Table 4.

Cytotoxicity of A2 and A5 on mammalian cells.

Cpd.	IC50 against HK-2	IC50 against L929
A2	78.25 μM (∼43.2 μg/mL)	82.74 μM (∼45.7 μg/mL)
A5	73.85 μM (∼40.5 μg/mL)	78.65 μM (∼43.1 μg/mL)

Conclusion

In conclusion, a series of new quinolinum derivatives were synthesized by systematically varying a styryl substituent at the ortho-position of 1-methylquinolinium core and their in vitro antibacterial activities were investigated comprehensively. The results indicate that these compounds possess significant antibacterial activity against the tested pathogens including the drug-resistant strains of MRSA, VRE, and NDM-1 E. coli. It is noteworthy that the MIC values of several compounds (A1, A2, A3, A5, A6, and A7) against MRSA strains are range from 1.5 to 4 μg/mL. The MIC values were found comparable to vancomycin and much lower than that of methicillin. In addition, these quinolinum derivatives exhibited potent antibacterial activity against VREs. In particular, A2 has the MIC values against vancomycin-resistant E. faecalis and E. faecium of 2 μg/mL, which are significantly lower than the MIC values of vancomycin (MICs >64 μg/mL). Moreover, A2 and A5 can effectively inhibit the growth of multidrug-resistant Gram-negative strains with the MIC values lower than 8 μg/mL, which is much lower than that of methicillin (MICs >192 μg/mL). In addition, the cytotoxicty values of A2 and A5 are much higher than their MIC values, suggesting these compounds possess little or low toxicity on the mammalian cells. The investigation on the mode of action revealed that the selected compounds can effectively disrupt the GTPase activity and polymerization of FtsZ in a dose-dependent manner. These results suggest that the interaction between quinolinum derivatives and the C-terminal interdomain cleft interferes with the GTPase activity of FtsZ, which in turn disrupts the polymerization of FtsZ, leading to the abnormal bacterial cell division and inhibition of cell proliferation. Therefore, the quinolinum derivatives could be useful in the development of antibacterial agents against drug resistant pathogens.

Funding Statement

We acknowledge the support from the National Natural Science Foundation of China [81473082, 81703333 and 81602608], Natural Science Foundation of Guangdong Province, China [2017A030313078], and Science and Technology Program of Guangdong Province [2016A020209009, 2016B020211002 and 510093637143].

Acknowledgements

The authors are also grateful to the support from Nanshan Scholar Program of Guangzhou Medical University and Innovation and Technology Commission of Hong Kong, The Hong Kong Polytechnic University.

Disclosure statement

No potential conflict of interest was reported by the authors.